These findings suggest that the VEGF pathway plays a key role in developing the immune-hostile TME of osteosarcoma, and targeting the VEGF/VEGFR2 pathway is an effective strategy to overcome TME and improve the clinical efficacy of T cell immunotherapy in osteosarcoma [163]. Here, VEGFA is linked to osteosarcoma.